- Natural product: Cannabis (Cannabis sativa)
- Associated study: Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel
In Vivo Interaction Study
Irinotecan PK ± medicinal cannabis
No Effect (based on bioequivalence limits) was detected.
- CYP3A
Table 2
Results
Table 2.
| Sample | Compound measured | Value | Measurement | Study sequence | Additional information | N replicates |
|---|
Experimental Conditions
Parallel
Females
Males
Patients
No marijuana use
12
M = 7, F = 5
Age 58 (27-66)
All with metastatic cancer "for which irinotecan or docetaxel was considered an adequate option, which was refractory to conventional treatment or for which there was no standard regimen."
Please refer to Table 1 in the text for further information
Immediate prior infusion, 30 min before end of infusion (EOI); at 10, 20, 30 min, 1, 1.5, 2, 3, 4, 5, 6, 22.5, 30, 46.5, and 54 hr after EOI
Drug or Natural Product Administration
Intravenous
Injection (250 mL NSS)
600 mg for first treatment, 450 mg or as per previous response
QW
90-min infusion, 1 week
Oral
Solution
18% THC, 0.8% CBD (200 mL, 1 g/L)
QPM
15 days starting day 10 of first treatment
Office for Medicinal Cannabis, The Hague, The Netherlands
Herbal tea
Not specified
Pharmacodynamics (PD) & Adverse Events
Hepatobiliary disorders
35900000
Immune system disorders
36000000
Varying degrees of reduction of WBC and neutrophil count. Please refer to Table 4 for further information.
Hepatobiliary disorders
35900000
Immune system disorders
36000000
Varying degrees of reduction of WBC and neutrophil count. Please refer to Table 4 for further information.